Biblio
Export 1756 results:
Author Title Type [ Year] Filters: First Letter Of Last Name is L [Clear All Filters]
“Progression from Subjective Cognitive Decline to Mild Cognitive Impairment or Dementia: The Role of Baseline Cognitive Performance.”, J Alzheimers Dis, vol. 86, no. 4, pp. 1763-1774, 2022.
, “Psychosis as a Treatment Target in Dementia: A Roadmap for Designing Interventions.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1203-1228, 2022.
, “Race Differences in the Association Between Sleep Medication Use and Risk of Dementia.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1133-1139, 2022.
, “Risk of Alzheimer's Disease Following Influenza Vaccination: A Claims-Based Cohort Study Using Propensity Score Matching.”, J Alzheimers Dis, vol. 88, no. 3, pp. 1061-1074, 2022.
, “The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1567-1580, 2022.
, “The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1567-1580, 2022.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Scavenging Reactive Oxygen Species Decreases Amyloid-β Levels via Activation of PI3K/Akt/GLUT1 Pathway in N2a/APP695swe Cells.”, J Alzheimers Dis, vol. 90, no. 1, pp. 185-198, 2022.
, “Scavenging Reactive Oxygen Species Decreases Amyloid-β Levels via Activation of PI3K/Akt/GLUT1 Pathway in N2a/APP695swe Cells.”, J Alzheimers Dis, vol. 90, no. 1, pp. 185-198, 2022.
, “Scavenging Reactive Oxygen Species Decreases Amyloid-β Levels via Activation of PI3K/Akt/GLUT1 Pathway in N2a/APP695swe Cells.”, J Alzheimers Dis, vol. 90, no. 1, pp. 185-198, 2022.
, “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
, “Small RNA Sequencing in the Tg4-42 Mouse Model Suggests the Involvement of snoRNAs in the Etiology of Alzheimer's Disease.”, J Alzheimers Dis, vol. 87, no. 4, pp. 1671-1681, 2022.
, “Subjective Cognitive Decline: Is a Resilient Personality Protective Against Progression to Objective Cognitive Impairment? Findings from Two Community-Based Cohort Studies.”, J Alzheimers Dis, vol. 89, no. 1, pp. 87-105, 2022.
, “Subjective Cognitive Decline: Is a Resilient Personality Protective Against Progression to Objective Cognitive Impairment? Findings from Two Community-Based Cohort Studies.”, J Alzheimers Dis, vol. 89, no. 1, pp. 87-105, 2022.
, “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
, “Transcriptome and Translatome Regulation of Pathogenesis in Alzheimer's Disease Model Mice.”, J Alzheimers Dis, vol. 86, no. 1, pp. 365-386, 2022.
, “Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1627-1637, 2022.
, “Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1627-1637, 2022.
, “Weight Loss and Alzheimer's Disease in Down Syndrome.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1215-1227, 2022.
, “Weight Loss and Alzheimer's Disease in Down Syndrome.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1215-1227, 2022.
, “Weight Loss and Alzheimer's Disease in Down Syndrome.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1215-1227, 2022.
,